Clinical implications of troponin-T elevations following TAVR: Troponin Increase Following TAVR

J Cardiol. 2022 Feb;79(2):240-246. doi: 10.1016/j.jjcc.2021.08.030. Epub 2021 Sep 15.

Abstract

Background: Baseline and post-procedural elevations in serum troponin-T levels are associated with increased morbidity and mortality following transcatheter aortic valve replacement (TAVR). However, the prognostic impact of change in serum troponin-T level following TAVR remains unknown.

Methods: Among the patients with severe aortic stenosis who underwent TAVR, those with baseline serum troponin-T level ≥51.5 ng/L were excluded. The impact of increases in serum troponin-T level to an abnormally high range (≥51.5 ng/L) following TAVR on 2-year cardiovascular death or heart failure readmissions was investigated.

Results: Among 189 included patients (median 86 years old, 28% men), serum troponin-T level increased in 79 patients following TAVR. An increase in serum troponin-T was associated with a higher rate of 30-day adverse events, predominantly due to pacemaker implantation for complete atrio-ventricular block, and a higher 2-year cumulative incidence of the primary endpoint (hazard ratio 5.24, 95% confidence interval 1.64-16.8, p = 0.005) adjusted for the potential confounders.

Conclusion: Post-procedural increase in serum troponin-T level was associated with adverse clinical outcomes following TAVR.

Keywords: Aortic valve disease; Heart failure; Hemodynamics.

MeSH terms

  • Aged, 80 and over
  • Aortic Valve / surgery
  • Aortic Valve Stenosis*
  • Female
  • Humans
  • Male
  • Risk Factors
  • Time Factors
  • Transcatheter Aortic Valve Replacement* / adverse effects
  • Treatment Outcome
  • Troponin
  • Troponin T

Substances

  • Troponin
  • Troponin T